Classer les publications sur l'année
-
Économie de la santé
Influence of geographic access and socioeconomic characteristics on breast cancer outcomes: A systematic review.
CONTI B, BOCHATON A, CHARREIRE H, KITZIS-BONSANG H, DESPRÈS C, BAFFERT S, NGÔ C.
PLoS One ; 2022;17(7):e0271319
-
Autres
Management and Health Resource Use of Patients with Metastatic Renal Cell Carcinoma treated with Systemic Therapy over 2014-2017 in France: a National Real-World Study
ESCUDIER B, DE ZELICOURT M, BOUROUINA R, NEVORET C,THIERY-VUILLEMIN A
Clinical Genitourinary Cancer ; 2022;20(6):533-542
-
Biométrie et Analyses de bases de données
Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
HARROW B, FAGNANI F, NEVORET C, TRUONG-THANH XM, DE ZÉLICOURT M, DE MESTIER L.
Adv Ther ; 2022;39:1754-1771
-
Biométrie et Analyses de bases de données
Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis.
NEUZILLET C, EMERY C, TEISSIER C, BOUEE S, LIEVRE A.
Lancet Reg Health Eur ; 2022;15:100324
-
Biométrie et Analyses de bases de données
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study
GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C
Future Oncol ; 2020;16(16),1115-1124
-
Économie de la santé
Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study
FERRIER C, THEBAUT C, BAFFERT S, ASSELAIN B, ROUZIER R,HEQUET D
J Gynecol Obstet Hum Reprod ; 2020;50(6)
-
Biométrie et Analyses de bases de données
Effectiveness of sequencing TKIs in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): A French national medical-administrative claim database analysis
GIRARD N, BOUEE S, MORO-SIBILOT D, EMERY C, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C
Annals of Oncology ; 2019;30(5):v627-v628
-
Pharmaco-Epidémiologie
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study
GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C.
Future Oncol ; 2020;16(16),1115-1124
-
Économie de la santé
Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
HEQUET D, HUCHON C, SOILLY AL, ASSELAIN B, BERSENEFF H, TRICHOT C, COMBES A, ALVES K, NGUYEN T, ROUZIER R, BAFFERT S.
PLoS One ; 2019;14(7)
-
Biométrie et Analyses de bases de données
Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in france: real world data from the permanent sample of national health insurance beneficiairies.
LAFUMA A, COTTÉ FE, LE TOURNEAU C, EMERY C, GAUDIN AF, TORRETON E, GOURMELEN J, BONASTRE J.
J Med Econ ; 2019;22(7):698-705
-
Économie de la santé
Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
LIZÉE T, BASCH E, TRÉMOLIÈRES P, VOOG E, DOMONT J, PEYRAGA G, URBAN T, BENNOUNA J, SEPTANS A-L, BALAVOINE M, DETOURNAY B, DENIS F.
J Thorac Oncol ; 2019;14(6):1012-1020
-
Économie de la santé
Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study
ARFI A, BAFFERT S, SOILLY AL, HUCHON C, REYAL F, ASSELAIN B, NEFFATI S, ROUZIER R, HÉQUET D.
BMJ Open ; 2018;8(5):e020276
-
Santé Publique et Epidémiologie
Un outil de suivi et d’auto-évaluation du bon usage du médicament en cancérologie : l’observatoire du médicament d la FNCLCC
LATOUR JF, GAMEROFF S, GENEVE J, FAGNANI F
J Pharm Clin ; 26(3):151-157
-
Économie de la santé
Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2
FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL
Bulletin du Cancer ; 94(7):711-720
-
Économie de la santé
Invasive cervical cancer treatment costs in France
ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG
Bull Cancer ; 94(2):219-224